Hyuntae Kim (#3022)
- $ 1 B
- Biotech
- South Korea
- M
- 50 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Hyuntae Kim is CEO of South Korean biotechnology company Voronoi. Voronoi's two most promising cancer drug candidates are VRN10 and VRN11. Both started Phase 1 clinical trials in 2025. Voronoi was founded by Kim's younger brother, Hyun-seok, in 2015. The older Kim took over the company in 2016 and listed it on Korea's Kosdaq in 2022. Previously, Kim did stints as head of asset management at eBest Investment & Securities, Hanwha Investment & Securities and KB Securities.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Hyuntae Kim’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Hyuntae Kim’s net worth journey over the years, highlighting key growth phases and financial milestones.
© Iconic Billionaires